“Just as radiation therapy and chemotherapy identified a new way to treat cancer in the 20th century, Qu Biologics’ SSIs are identifying a new way for the 21st century.”
~ Dr. Simon Sutcliffe, Chief Medical Officer, Qu Biologics
Qu Biologics’ QBKPN SSI, derived from components of inactivated K. pneumoniae, is designed to stimulate an innate immune response in the lungs and reverse the immune dysfunction that underlies cancer development and progression. Qu has completed enrollment of a Health Canada-approved clinical trial at the BC Cancer Agency Research Centre to evaluate immunological response to SSI treatment in patients with recurrent lung cancer.
Restoring immune function to treat lung cancer
Unlike current treatments that target the cancer cells, Qu’s SSIs are designed to activate the patient’s own immune cells, restoring normal immune function. Treatment with lung targeted QBKPN SSI, derived from components of inactivated K. pneumoniae (a common lung pathogen), recruits activated innate immune cells to the lungs, re-establishing the body’s capacity to mount an effective anti-cancer immune response. Read more about How SSIs Work.
Qu Biologics’ lung cancer clinical trial
Qu Biologics has completed enrollment of a Health Canada-approved Phase 2a exploratory clinical trial to evaluate the mechanism of action and the safety, tolerability and compliance of QBKPN SSI treatment in patients with recurrent lung cancer. The study took place at the B.C. Cancer Agency and was led by Principal Investigator Dr. Stephen Lam, a leading Canadian lung cancer detection and prevention clinical researcher. The trial assesses the immunological effects of SSI treatment.
Promising Compassionate Use results
From 2008 to 2012, 105 patients with late stage primary lung cancer (40patients) or lung metastases (65 patients) were treated with Qu Biologics’ QBKPN SSI in a compassionate use program.
An independent research group initiated a case-matched study of late-stage cancer patients as a preliminary assessment of SSI efficacy, comparing survival of patients treated with SSI to survival of matched patients at the same clinic with the same type/stage of cancer not treated with SSIs. The median survival of advanced cancer patients treated with SSIs was 12 months longer than the median survival of matched patients not treated with SSIs. In patients with advanced lung cancer, SSI treated patients had a median survival advantage of 15 months compared to their matched cases not treated with SSI. Read more about the excellent safety profile and promising clinical data in Qu’s compassionate use program in advanced cancer.
This case-matched study was not randomized or prospective and therefore, no definitive conclusions can be drawn with respect to SSI efficacy. However, the results are promising and provide the precedent for our current Phase 2a clinical trial in recurrent lung cancer.
Preclinical research demonstrates QBKPN SSI treatment reduces lung tumour burden and increases survival in both lung cancer and lung metastases
Qu Biologics’ scientists have conducted numerous preclinical studies demonstrating the efficacy of QBKPN SSI for the treatment of cancer in the lungs. Read more about our preclinical studies in cancer.